Komori
Transgenic Group (2342) · PolicyPartial Sale of Cross-Shareholdings

Periodic Review of Strategic Shareholdings Based on Business Transactions and Alliances

First written in FY2019. 1 of 3 entries say "Restated". Latest entry: FY2026.

3entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019 – FY20262019: 120192020: 120202021: 020212022: 020222023: 020232024: 020242025: 020252026: 12026
Same theme, other companies
Review of the Rationale for Holding Strategic ShareholdingsA theme 1258 companies write about · 1 as a headwind · 666 as a tailwind

15 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 1262 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026Partial Sale of Cross-ShareholdingsAnnual report

    「The accounting and finance department reviews each quarter the status of transactions with investee companies, as well as their financial condition, operating performance, share prices and other relevant factors, and periodically reviews whether to continue holding the shares.」

    The company reconfirmed its policy of reviewing whether to continue holding shares each quarter, while its holding of Immuno-Biological Laboratories Co., Ltd. shares decreased from 205,000 shares to 160,000 shares, which were sold for ¥152.820 million.
  2. FY2020RestatedAnnual report

    「The accounting and finance department reviews each quarter the status of transactions with investee companies, as well as their financial condition, operating performance, share prices and other relevant factors, and periodically reviews whether to continue holding the shares.」

    The company has reconfirmed its quarterly review of cross-shareholdings based on business and partnership relationships and its review of whether to continue holding them.
  3. FY2019First statedAnnual report

    「As a general rule, the company does not hold shares for pure investment purposes. It invests in shares when it determines that doing so will help build stable business relationships or maintain and strengthen business alliances in line with its growth strategy, thereby contributing to the enhancement of corporate value over the medium to long term, and classifies such shares as investments held for purposes other than pure investment.」

    The company has stated for the first time its policy of generally not holding shares for pure investment purposes, holding shares based on their contribution to business relationships, business alliances and corporate value enhancement, and reviewing each quarter whether to continue holding them after checking transaction conditions and financial condition, among other matters.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Transgenic Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.